

Mustafa Ã-zgÃœeroglu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6423578/publications.pdf>

Version: 2024-02-01

242
papers

22,886
citations

76196

40
h-index

9073

144
g-index

249
all docs

249
docs citations

249
times ranked

18942
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. <i>Gastric Cancer</i> , 2022, 25, 197-206. | 2.7 | 72 |
| 2 | A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 106-115. | 3.2 | 18 |
| 3 | Comparison of iodine-125 plaque brachytherapy and gamma knife stereotactic radiosurgery treatment outcomes for uveal melanoma patients. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2022, 260, 1337-1343. | 1.0 | 4 |
| 4 | Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). <i>Gastric Cancer</i> , 2022, 25, 586-597. | 2.7 | 8 |
| 5 | Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study. <i>European Journal of Cancer</i> , 2022, 162, 56-64. | 1.3 | 14 |
| 6 | An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction. <i>The Journal of Breast Health</i> , 2022, 18, 63-73. | 0.4 | 0 |
| 7 | Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Nonâ€Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311. | 0.8 | 445 |
| 8 | Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). <i>Lung Cancer</i> , 2022, 166, 107-113. | 0.9 | 3 |
| 9 | Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. <i>Lung Cancer</i> , 2022, 166, 84-93. | 0.9 | 7 |
| 10 | Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.. <i>Journal of Clinical Oncology</i> , 2022, 40, 519-519. | 0.8 | 0 |
| 11 | Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. <i>Cancers</i> , 2022, 14, 1168. | 1.7 | 0 |
| 12 | Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro + chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.. <i>Journal of Clinical Oncology</i> , 2022, 40, 540-540. | 0.8 | 1 |
| 13 | First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 521-521. | 0.8 | 0 |
| 14 | The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN.. <i>Journal of Clinical Oncology</i> , 2022, 40, 89-89. | 0.8 | 4 |
| 15 | CLOZZ-074: Patient-Reported Outcomes (PROs) in Patients (pts) With Advanced Non-Small Cell Lung Cancer (aNSCLC) With Programmed Cell Death-Ligand 1 (PD-L1) â€¥50% Receiving Cemiplimab (CEMI) Monotherapy Versus Platinum-Doublet Chemotherapy (CHEMO): A Focus on the EMPOWER-Lung 1 Brain Metastases Subpopulation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 0122-074. | 2.3 | 0 |
| 16 | Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. <i>European Journal of Cancer</i> , 2022, 170, 73-84. | 1.3 | 10 |
| 17 | Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5019-5019. | 0.8 | 2 |
| 18 | Adverse events self-reported by patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with durvalumab (D) plus platinum-etoposide (EP) or EP in the CASPIAN study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8571-8571. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Genomic aberrations associated with overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or placebo (PBO) plus androgen deprivation therapy (ADT) in TITAN.. Journal of Clinical Oncology, 2022, 40, 5066-5066. | 0.8 | 4 |
| 20 | Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer. Tumori, 2021, 107, 304-310. | 0.6 | 3 |
| 21 | PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. Future Oncology, 2021, 17, 137-149. | 1.1 | 5 |
| 22 | Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. Journal of Clinical Oncology, 2021, 39, 966-977. | 0.8 | 122 |
| 23 | Durvalumab, with or without tremelimumab, plus platinum+etoposide versus platinum+etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 51-65. | 5.1 | 356 |
| 24 | Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer, 2021, 151, 30-38. | 0.9 | 30 |
| 25 | The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer. Medical Oncology, 2021, 38, 11. | 1.2 | 0 |
| 26 | Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.. Journal of Clinical Oncology, 2021, 39, 435-435. | 0.8 | 1 |
| 27 | Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet, The, 2021, 397, 592-604. | 6.3 | 441 |
| 28 | 1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.. Journal of Clinical Oncology, 2021, 39, 450-450. | 0.8 | 10 |
| 29 | Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2021, 39, 439-439. | 0.8 | 2 |
| 30 | Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2021, 39, 11-11. | 0.8 | 6 |
| 31 | Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.. Journal of Clinical Oncology, 2021, 39, 321-321. | 0.8 | 1 |
| 32 | Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2021, 39, 448-448. | 0.8 | 2 |
| 33 | A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. Oncologist, 2021, 26, e769-e779. | 1.9 | 48 |
| 34 | A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, 531-540. | 1.1 | 15 |
| 35 | Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial. Lung Cancer, 2021, 154, 92-98. | 0.9 | 3 |
| 36 | Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncology, 2021, 17, 1165-1184. | 1.1 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2021, 39, 5068-5068. | 0.8 | 2 |
| 38 | Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 â%¥ 50%: Results from EMPOWER-Lung 1 study.. Journal of Clinical Oncology, 2021, 39, 9078-9078. | 0.8 | 3 |
| 39 | Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.. Journal of Clinical Oncology, 2021, 39, 8511-8511. | 0.8 | 74 |
| 40 | Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLCâ€”an Update From the PACIFIC Trial. Journal of Thoracic Oncology, 2021, 16, 860-867. | 0.5 | 323 |
| 41 | Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) â%¥ 50%: EMPOWER-Lung 1 subgroup analysis.. Journal of Clinical Oncology, 2021, 39, 9085-9085. | 0.8 | 6 |
| 42 | Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instabilityâ€”High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncology, 2021, 7, 895. | 3.4 | 184 |
| 43 | Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Nonâ€”Smallâ€”Cell Lung Cancer (PACIFIC). Clinical Lung Cancer, 2021, 22, 549-561. | 1.1 | 25 |
| 44 | Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 931-945. | 5.1 | 337 |
| 45 | Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. Journal of Clinical Oncology, 2021, 39, 2294-2303. | 0.8 | 218 |
| 46 | Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Nonâ€”small-cell Lung Cancer: LAURA Trial in Progress. Clinical Lung Cancer, 2021, 22, 371-375. | 1.1 | 44 |
| 47 | Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. Journal of Thoracic Oncology, 2021, 16, 1369-1378. | 0.5 | 31 |
| 48 | Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. Gastric Cancer, 2021, 24, 1330-1340. | 2.7 | 7 |
| 49 | Reply by Authors. Journal of Urology, 2021, 206, 923-923. | 0.2 | 0 |
| 50 | Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study. Journal of Urology, 2021, 206, 914-923. | 0.2 | 9 |
| 51 | Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. Future Oncology, 2021, 17, 4861-4869. | 1.1 | 2 |
| 52 | Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCâ€”Update from PACIFIC. Journal of Thoracic Oncology, 2020, 15, 288-293. | 0.5 | 328 |
| 53 | Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. European Urology, 2020, 77, 494-500. | 0.9 | 54 |
| 54 | Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis. European Urology Open Science, 2020, 19, e863-e864. | 0.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. Annals of Oncology, 2020, 31, S1182-S1183. | 0.6 | 18 |
| 56 | LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. Annals of Oncology, 2020, 31, S1212-S1213. | 0.6 | 23 |
| 57 | 6100 Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. Annals of Oncology, 2020, 31, S508. | 0.6 | 7 |
| 58 | LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial. Annals of Oncology, 2020, 31, S1178-S1179. | 0.6 | 24 |
| 59 | O81...IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1-selected NSCLC. , 2020, , . | | 6 |
| 60 | Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer, 2020, 149, 46-52. | 0.9 | 28 |
| 61 | Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2020, 383, 2345-2357. | 13.9 | 440 |
| 62 | 1459P Albumin as a simple criterion to reduce early mortality (EM) in gastric cancer (GC) trials. Annals of Oncology, 2020, 31, S915. | 0.6 | 1 |
| 63 | 624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound. Annals of Oncology, 2020, 31, S515-S516. | 0.6 | 0 |
| 64 | 651P Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study. Annals of Oncology, 2020, 31, S530-S531. | 0.6 | 0 |
| 65 | 374TiP LAURA: Osimertinib maintenance following definitive chemoradiation therapy (CRT) in patients (pts) with unresectable stage III epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC). Annals of Oncology, 2020, 31, S1385. | 0.6 | 2 |
| 66 | 378MO EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. Annals of Oncology, 2020, 31, S1388. | 0.6 | 5 |
| 67 | 379MO Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. Annals of Oncology, 2020, 31, S1388-S1389. | 0.6 | 2 |
| 68 | LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. Annals of Oncology, 2020, 31, S1155. | 0.6 | 49 |
| 69 | Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2020, 395, 1547-1557. | 6.3 | 546 |
| 70 | Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Annals of Oncology, 2020, 31, 798-806. | 0.6 | 131 |
| 71 | O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology, 2020, 31, 236. | 0.6 | 6 |
| 72 | Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. New England Journal of Medicine, 2020, 383, 1328-1339. | 13.9 | 959 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Pembrolizumab versus paclitaxel for previously treated patients with PD-L1â€“positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.. Journal of Clinical Oncology, 2020, 38, 4503-4503. | 0.8 | 31 |
| 74 | The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.. Journal of Clinical Oncology, 2020, 38, 4512-4512. | 0.8 | 26 |
| 75 | The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.. Journal of Clinical Oncology, 2020, 38, 4537-4537. | 0.8 | 38 |
| 76 | Durvalumab Â± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.. Journal of Clinical Oncology, 2020, 38, 9002-9002. | 0.8 | 36 |
| 77 | Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).. Journal of Clinical Oncology, 2020, 38, 9048-9048. | 0.8 | 1 |
| 78 | First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.. Journal of Clinical Oncology, 2020, 38, 9068-9068. | 0.8 | 10 |
| 79 | Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2âˆ“ advanced gastric or gastroesophageal junction cancer (G/GEJC).. Journal of Clinical Oncology, 2020, 38, 278-278. | 0.8 | 39 |
| 80 | Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.. Journal of Clinical Oncology, 2020, 38, 430-430. | 0.8 | 20 |
| 81 | PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.. Journal of Clinical Oncology, 2020, 38, 134-134. | 0.8 | 6 |
| 82 | Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane).. Journal of Clinical Oncology, 2020, 38, 82-82. | 0.8 | 12 |
| 83 | Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease.. Journal of Clinical Oncology, 2020, 38, 87-87. | 0.8 | 5 |
| 84 | PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2020, 38, TPS589-TPS589. | 0.8 | 0 |
| 85 | Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.. Journal of Clinical Oncology, 2020, 38, e13646-e13646. | 0.8 | 0 |
| 86 | Abstract CT213: Impact of smoking on outcomes with durvalumab following chemoradiotherapy in unresectable Stage III NSCLC (PACIFIC). , 2020, , . | | 0 |
| 87 | CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab Â± Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab Â± Tremelimumab + Chemotherapie beim Extensive Stage kleinzelligen Lungenkarzinom (ES-SCLC). , 2020, 74. , . | | 0 |
| 88 | PD10-11â€“APALUTAMIDE FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER IN TITAN: PROGNOSTIC IMPORTANCE OF PROSTATE-SPECIFIC ANTIGEN RESPONSES. Journal of Urology, 2020, 203, . | 0.2 | 0 |
| 89 | Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061). Annals of Oncology, 2019, 30, v304. | 0.6 | 2 |
| 90 | Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC). Annals of Oncology, 2019, 30, v330-v331. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC). <i>Annals of Oncology</i> , 2019, 30, v592-v593. | 0.6 | 11 |
| 92 | Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2019, 30, v611-v612. | 0.6 | 3 |
| 93 | PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN. <i>Annals of Oncology</i> , 2019, 30, v928-v929. | 0.6 | 32 |
| 94 | A challenging task â€“ Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience. <i>Annals of Oncology</i> , 2019, 30, v813-v814. | 0.6 | 3 |
| 95 | IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1â€“selected NSCLC. <i>Annals of Oncology</i> , 2019, 30, v915. | 0.6 | 97 |
| 96 | Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1670-1680. | 5.1 | 125 |
| 97 | Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1518-1530. | 5.1 | 69 |
| 98 | PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, S7-S8. | 0.5 | 17 |
| 99 | Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. <i>Annals of Oncology</i> , 2019, 30, v328-v329. | 0.6 | 32 |
| 100 | Durvalumab plus platinumâ€“etoposide versus platinumâ€“etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 394, 1929-1939. | 6.3 | 1,274 |
| 101 | Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 13-24. | 13.9 | 904 |
| 102 | Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 686-700. | 5.1 | 496 |
| 103 | KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. <i>Future Oncology</i> , 2019, 15, 1057-1066. | 1.1 | 132 |
| 104 | IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). <i>Annals of Oncology</i> , 2019, 30, v888-v889. | 0.6 | 28 |
| 105 | Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience. <i>Annals of Oncology</i> , 2019, 30, xi19. | 0.6 | 0 |
| 106 | Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia. <i>Annals of Oncology</i> , 2019, 30, ix197-ix198. | 0.6 | 1 |
| 107 | Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. <i>Clinical Lung Cancer</i> , 2019, 20, e407-e412. | 1.1 | 12 |
| 108 | Three-year overall survival update from the PACIFIC trial. <i>Annals of Oncology</i> , 2019, 30, ix108-ix109. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.. Journal of Clinical Oncology, 2019, 37, 4037-4037. | 0.8 | 5 |
| 110 | First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2019, 37, 5006-5006. | 0.8 | 4 |
| 111 | Three-year overall survival update from the PACIFIC trial.. Journal of Clinical Oncology, 2019, 37, 8526-8526. | 0.8 | 29 |
| 112 | First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.. Journal of Clinical Oncology, 2019, 37, 9054-9054. | 0.8 | 3 |
| 113 | Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2019, 37, 141-141. | 0.8 | 7 |
| 114 | Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study. Annals of Oncology, 2019, 30, ix68. | 0.6 | 0 |
| 115 | Durvalumab in Stage III Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 868-870. | 13.9 | 33 |
| 116 | An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting. European Journal of Cancer, 2018, 92, S102-S103. | 1.3 | 2 |
| 117 | Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents. Clinical Genitourinary Cancer, 2018, 16, e777-e784. | 0.9 | 20 |
| 118 | Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. JAMA Oncology, 2018, 4, 977. | 3.4 | 48 |
| 119 | Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry. Journal of Global Oncology, 2018, 4, 1-12. | 0.5 | 11 |
| 120 | Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC. Annals of Oncology, 2018, 29, viii488. | 0.6 | 25 |
| 121 | Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. Annals of Oncology, 2018, 29, viii413. | 0.6 | 12 |
| 122 | P1.16-04 Outcomes of Patients <70 or ≥70 Years of Age in PACIFIC. Journal of Thoracic Oncology, 2018, 13, S628-S629. | 0.5 | 2 |
| 123 | P1.16-06 Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%. Journal of Thoracic Oncology, 2018, 13, S629-S630. | 0.5 | 0 |
| 124 | PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1607-1608. | 0.4 | 2 |
| 125 | PL02.01 Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC. Journal of Thoracic Oncology, 2018, 13, S184. | 0.5 | 6 |
| 126 | OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial. Journal of Thoracic Oncology, 2018, 13, S331-S332. | 0.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | P1.16-05 Effect of Induction Chemotherapy in the PACIFIC Study. Journal of Thoracic Oncology, 2018, 13, S629. | 0.5 | 1 |
| 128 | MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT. Journal of Thoracic Oncology, 2018, 13, S370-S371. | 0.5 | 35 |
| 129 | Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncology, The, 2018, 19, 1468-1479. | 5.1 | 370 |
| 130 | Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine, 2018, 379, 2342-2350. | 13.9 | 2,150 |
| 131 | 2330 Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes. Journal of Thoracic Oncology, 2018, 13, S71. | 0.5 | 0 |
| 132 | Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer. JAMA Oncology, 2018, 4, 1367. | 3.4 | 67 |
| 133 | KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer. Annals of Oncology, 2018, 29, v123. | 0.6 | 29 |
| 134 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133. | 6.3 | 984 |
| 135 | Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.. Journal of Clinical Oncology, 2018, 36, 1005-1005. | 0.8 | 2 |
| 136 | Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.. Journal of Clinical Oncology, 2018, 36, 4062-4062. | 0.8 | 10 |
| 137 | Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR) Tj ETQq1 1 0.784314 rgBT /Overlo | 0.8 | 1 |
| 138 | Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial.. Journal of Clinical Oncology, 2018, 36, 5028-5028. | 0.8 | 1 |
| 139 | Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.. Journal of Clinical Oncology, 2018, 36, TPS9117-TPS9117. | 0.8 | 1 |
| 140 | JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).. Journal of Clinical Oncology, 2018, 36, TPS195-TPS195. | 0.8 | 12 |
| 141 | Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine, 2017, 377, 352-360. | 13.9 | 1,588 |
| 142 | Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study. Clinical Genitourinary Cancer, 2017, 15, e469-e476. | 0.9 | 11 |
| 143 | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 1919-1929. | 13.9 | 3,261 |
| 144 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1688-1700. | 5.1 | 451 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | PL 02.02 Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1604. | 0.5 | 4 |
| 146 | PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC. <i>Annals of Oncology</i> , 2017, 28, v634. | 0.6 | 4 |
| 147 | Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2~) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1010-1010. | 0.8 | 6 |
| 148 | LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA3-LBA3. | 0.8 | 2 |
| 149 | Abstract P2-11-08: Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial. , 2017, , . | | 0 |
| 150 | TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC). <i>Annals of Oncology</i> , 2016, 27, vi265. | 0.6 | 6 |
| 151 | Cost of Treatment of HR+/HER2- Post Menopausal Advanced/Metastatic Breast Cancer Patients in Turkey. <i>Value in Health</i> , 2016, 19, A146. | 0.1 | 1 |
| 152 | Abstract P4-13-12: Everolimus plus trastuzumab and vinorelbine for trastuzumab-resistant, taxane-pretreated, HER2+ advanced breast cancer: Overall survival results from BOLERO-3. , 2016, , . | | 2 |
| 153 | Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9105-TPS9105. | 0.8 | 6 |
| 154 | 2549 Treatment patterns in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC) previously treated with docetaxel (DOC)-based chemotherapy (CT): PROXIMA 1-year analysis. <i>European Journal of Cancer</i> , 2015, 51, S492-S493. | 1.3 | 0 |
| 155 | 2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel. <i>European Journal of Cancer</i> , 2015, 51, S488. | 1.3 | 0 |
| 156 | 2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting. <i>European Journal of Cancer</i> , 2015, 51, S489. | 1.3 | 2 |
| 157 | 2612 Prognostic value of baseline Neutrophil to Lymphocyte Ratio (NLR) in metastatic Urothelial Carcinomas (mUC) patients (pts) treated with first-line chemotherapy (CT): A large retrospective multicenter study. <i>European Journal of Cancer</i> , 2015, 51, S515-S516. | 1.3 | 0 |
| 158 | Clinical experience with Vemurafenib in pretreated melanoma (MEL): The results of open label multi center study from Turkey.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20085-e20085. | 0.8 | 0 |
| 159 | Receptor Expression Discrepancy between Primary and Metastatic Breast Cancer Lesions. <i>Oncology Research and Treatment</i> , 2014, 37, 622-626. | 0.8 | 9 |
| 160 | Quality-of-Life in Turkish Cancer Patients: The Impact of Sociodemographic Characteristics, Medical History, and Management.. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2014, 24, 23-29. | 0.1 | 2 |
| 161 | Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 580-591. | 5.1 | 434 |
| 162 | Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. <i>British Journal of Cancer</i> , 2014, 110, 1968-1976. | 2.9 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2014, 50, 1602-1609. | 1.3 | 50 |
| 164 | Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 282-282. | 0.8 | 16 |
| 165 | Re: Germline BRCA Mutations are Associated with Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. <i>Journal of Urology</i> , 2013, 190, 2093-2094. | 0.2 | 3 |
| 166 | Dendritic cell sarcoma: A pooled analysis including 462 cases with presentation of our case series. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 253-271. | 2.0 | 195 |
| 167 | Primary Osteosarcoma of the Heart: Experience of an Unusual Case. <i>Case Reports in Oncology</i> , 2013, 6, 224-228. | 0.3 | 7 |
| 168 | Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. <i>Annals of Oncology</i> , 2013, 24, 2402-2408. | 0.6 | 126 |
| 169 | Patterns of Complementary and Alternative Medicine Use among Turkish Cancer Patients. <i>Journal of Palliative Medicine</i> , 2013, 16, 383-390. | 0.6 | 27 |
| 170 | Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience. <i>World Journal of Gastroenterology</i> , 2013, 19, 2154. | 1.4 | 11 |
| 171 | A Case of Complete Response to Letrozol Treatment in a Postmenopausal Woman With Breast Cancer Who has Progressed After Multiple Lines of Chemotherapy. <i>World Journal of Oncology</i> , 2013, 4, 58-60. | 0.6 | 1 |
| 172 | Clinicopathological Features and Localization of Gastric Cancers and their Effects on Survival in Turkey. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 553-556. | 0.5 | 8 |
| 173 | Abstract P4-12-18: BOLERO-3: Quality-of-life maintained in patients with metastatic breast cancer treated with everolimus plus trastuzumab plus vinorelbine. , 2013, , . | | 0 |
| 174 | Breast carcinoma metastasis to endometrial polyp (Case report and literature review). <i>Cumhuriyet Medical Journal</i> , 2013, 35, 589-592. | 0.1 | 0 |
| 175 | Primary Gastric Lymphoma: Conservative Treatment Modality Is Not Inferior to Surgery for Early-Stage Disease. <i>ISRN Oncology</i> , 2012, 2012, 1-6. | 2.1 | 8 |
| 176 | Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain. <i>Onkologie</i> , 2012, 35, 254-258. | 1.1 | 8 |
| 177 | Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3640-3647. | 0.8 | 166 |
| 178 | A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. <i>Journal of Clinical Oncology</i> , 2012, 30, 172-172. | 0.8 | 1 |
| 179 | Prognostic factors for survival in the phase III TROPIC trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 102-102. | 0.8 | 1 |
| 180 | A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15112-e15112. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | 7044 POSTER Cabazitaxel Plus Prednisone for Patients With Metastatic Castration-resistant Prostate Cancer Previously Treated With a Docetaxel-containing Regimen " Interim Analysis Results From an Ongoing Compassionate-use Programme. <i>European Journal of Cancer</i> , 2011, 47, S498. | 1.3 | 0 |
| 182 | 6037 POSTER Preoperative Chemoradiotherapy Improves Local Recurrence Free Survival in Locally Advanced Rectal Cancer. <i>European Journal of Cancer</i> , 2011, 47, S402. | 1.3 | 0 |
| 183 | 5046 POSTER Tumour Characteristics Determining Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. <i>European Journal of Cancer</i> , 2011, 47, S344. | 1.3 | 0 |
| 184 | 6020 POSTER KRas and Braf: Is a Predictor in Metastatic Colorectal Cancer Patients for Bevacizumab?. <i>European Journal of Cancer</i> , 2011, 47, S397. | 1.3 | 0 |
| 185 | Synchronous Detection of Hairy Cell Leukemia and HIV-Negative Kaposi's Sarcoma of the Lymph Node: A Diagnostic Challenge and a Rare Coincidence. <i>Case Reports in Oncology</i> , 2011, 4, 439-444. | 0.3 | 3 |
| 186 | Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, 4525-4525. | 0.8 | 12 |
| 187 | A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 4526-4526. | 0.8 | 13 |
| 188 | Impact of G-CSF prophylaxis on the occurrence of neutropenia in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel.. <i>Journal of Clinical Oncology</i> , 2011, 29, e15131-e15131. | 0.8 | 1 |
| 189 | Effect of G-CSF prophylaxis on the occurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the TROPIC study.. <i>Journal of Clinical Oncology</i> , 2011, 29, 144-144. | 0.8 | 8 |
| 190 | Primary diffuse large B cell lymphoma of the breast eight years after the diagnosis of gastric MALT lymphoma: report of first case. <i>Archives of Gynecology and Obstetrics</i> , 2010, 282, 587-590. | 0.8 | 5 |
| 191 | Gastroenteropancreatic neuroendocrine tumors: 10-year experience in a single center. <i>Medical Oncology</i> , 2010, 27, 1050-1056. | 1.2 | 13 |
| 192 | Surgery for Isolated Liver Metastasis of Ovarian Cancer. <i>Asian Journal of Surgery</i> , 2010, 33, 83-88. | 0.2 | 13 |
| 193 | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. <i>Lancet, The</i> , 2010, 376, 1147-1154. | 6.3 | 2,857 |
| 194 | Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC).. <i>Journal of Clinical Oncology</i> , 2010, 28, 4508-4508. | 0.8 | 49 |
| 195 | Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain.. <i>Journal of Clinical Oncology</i> , 2010, 28, e19507-e19507. | 0.8 | 1 |
| 196 | How does 18f-FDG PET-CT scan affect clinical judgment and change treatment decisions in patients with epithelial ovarian cancer?. <i>Journal of Clinical Oncology</i> , 2010, 28, 5053-5053. | 0.8 | 0 |
| 197 | Is There Any Effect of Tumor Burden on Hemostatic Parameters in Cancer Patients? A Case-Control Study of Hemostatic Abnormalities and Anticardiolipin Antibodies in Solid Tumors. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 454-457. | 0.7 | 5 |
| 198 | Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study. <i>Medical Oncology</i> , 2008, 25, 257-263. | 1.2 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Determining predominating histologic component in malignant mixed mllerian tumors: is it worth it?. International Journal of Gynecological Cancer, 2008, 18, 809-812. | 1.2 | 17 |
| 200 | Paraneoplastic pemphigus associated with fludarabine use. Medical Oncology, 2007, 24, 115-118. | 1.2 | 17 |
| 201 | Thymoma with chronic diarrhea. Medical Oncology, 2007, 24, 119-123. | 1.2 | 5 |
| 202 | C-reactive protein as an acute phase protein in cancer patients. Medical Oncology, 2007, 24, 338-344. | 1.2 | 15 |
| 203 | A caseâ€“control study of non-alcoholic fatty liver disease in breast cancer. Medical Oncology, 2007, 24, 367-371. | 1.2 | 36 |
| 204 | Devastating effects of chemotherapy: deafness and acute renal failure in a patient with epithelial ovarian cancer. International Journal of Gynecological Cancer, 2006, 16, 394-396. | 1.2 | 8 |
| 205 | Adult Paratesticular Myxofibrosarcoma: Report of a Rare Entity and Review of the Literature. International Urology and Nephrology, 2006, 38, 5-7. | 0.6 | 16 |
| 206 | Small Cell Carcinoma of the Bladder: A Case Report and Review of the Literature. International Urology and Nephrology, 2006, 38, 15-19. | 0.6 | 7 |
| 207 | Skeletal muscle: An unusual site of distant metastasis in gastric carcinoma. Radiation Medicine, 2006, 24, 150-153. | 0.8 | 28 |
| 208 | Megestrol acetate induced hypoadrenalism with cushingoid phenotype in endometrial cancer. Gynecologic Oncology, 2006, 101, 183. | 0.6 | 3 |
| 209 | Idiopathic thrombocytopenia associated with dysgerminoma in a patient with androgen insensitivity syndrome. Gynecologic Oncology, 2005, 99, 248. | 0.6 | 2 |
| 210 | Toxicity and Survival Results of a Phase II Study Investigating the Role of Postoperative Chemo-radioimmunotherapy for Gastric Adenocarcinoma. Strahlentherapie Und Onkologie, 2005, 181, 652-659. | 1.0 | 8 |
| 211 | Does the incidence of anal canal cancers differ in Moslem societies?. International Journal of Colorectal Disease, 2005, 20, 76-76. | 1.0 | 1 |
| 212 | Role of the antiangiogenetic drug paclitaxel on healing of intestinal anastomosis: an experimental study. Techniques in Coloproctology, 2005, 9, 201-205. | 0.8 | 3 |
| 213 | Secretory Carcinoma of the Breast. Oncology, 2005, 68, 263-268. | 0.9 | 30 |
| 214 | Delayed onset bleomycin-induced pneumonitis. Urology, 2005, 66, 195. | 0.5 | 33 |
| 215 | Reactivation of Hepatitis B Virus Infection with Cytotoxic Therapy in Non-Hodgkin's Lymphoma. Medical Oncology, 2004, 21, 67-72. | 1.2 | 39 |
| 216 | Should Mammographic Screening Be Done in Primary Ovarian Cancer?: A Case Control Study in Turkish Women. Medical Oncology, 2004, 21, 139-144. | 1.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Rituximab-Induced Tumor Progression: Does It Really Happen?. <i>Medical Oncology</i> , 2004, 21, 205-206. | 1.2 | 10 |
| 218 | Acute Leukemia in a Patient with Ocular Melanoma: Is It Induced by Intraocular Brachytherapy or Only a Bad Fate?. <i>Medical Oncology</i> , 2004, 21, 373-374. | 1.2 | 0 |
| 219 | Is the incidence of anal canal cancers different in Moslem societies?. <i>Journal of Clinical Oncology</i> , 2004, 22, 4233-4233. | 0.8 | 0 |
| 220 | Gastric cancer in Turkey: A single center experience of 683 cases. <i>Journal of Clinical Oncology</i> , 2004, 22, 4254-4254. | 0.8 | 0 |
| 221 | Intrathoracic Extravasation of Antineoplastic Agents. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 121-123. | 0.6 | 44 |
| 222 | Primary granulocytic sarcoma of the urinary bladder: case report and review of the literature. <i>Urology</i> , 2002, 60, 345. | 0.5 | 29 |
| 223 | Simultaneous Presentation of Hepatocellular Carcinoma in Identical Twin Brothers. <i>Medical Oncology</i> , 2002, 19, 113-116. | 1.2 | 13 |
| 224 | Flutamide-Induced Acute Renal Failure in a Patient with Metastatic Prostate Cancer. <i>Medical Oncology</i> , 2002, 19, 117-120. | 1.2 | 11 |
| 225 | Metastatic cardiac myxoma. <i>Annals of Thoracic Surgery</i> , 2001, 72, 623-625. | 0.7 | 18 |
| 226 | Serum erythropoietin level in anemic cancer patients. <i>Medical Oncology</i> , 2000, 17, 29-34. | 1.2 | 32 |
| 227 | Unusual Manifestations of B-Cell Disorders. <i>Journal of Clinical Oncology</i> , 1999, 17, 1083-1083. | 0.8 | 9 |
| 228 | Serum Cardiolipin Antibodies in Cancer Patients with Thromboembolic Events. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, 181-184. | 0.7 | 17 |
| 229 | Magnetic resonance imaging of bone marrow versus bone marrow biopsy in malignant lymphoma. <i>Pathology and Oncology Research</i> , 1999, 5, 123-128. | 0.9 | 6 |
| 230 | Serum erythropoietin level in anemic cancer patients. <i>European Journal of Cancer</i> , 1999, 35, S105. | 1.3 | 0 |
| 231 | Chemoimmunotherapy protocol for advanced gastric cancer. <i>European Journal of Cancer</i> , 1999, 35, S152. | 1.3 | 0 |
| 232 | Role of mammographic screening in ovarian cancer. <i>European Journal of Cancer</i> , 1999, 35, S245. | 1.3 | 0 |
| 233 | Anaphylaxis From Intraperitoneal Infusion of Cisplatin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 172-173. | 0.6 | 7 |
| 234 | Microangiopathic Hemolytic Anemia As an Early Predictor of Recurrence in Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 214. | 0.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Bilateral Inflammatory Breast Metastases of Epithelial Ovarian Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 408-410. | 0.6 | 32 |
| 236 | Paraneoplastic Hyperpigmentation Secondary to Lung Cancer Resolving After Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 533. | 0.6 | 1 |
| 237 | Usefulness of the Epithelial Tumor Marker CA-125 in Non-Hodgkinâ€™s Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 615. | 0.6 | 21 |
| 238 | Primary Splenic Tuberculosis in a Patient With Nasal Angiocentric Lymphoma. Journal of Clinical Gastroenterology, 1999, 29, 96-98. | 1.1 | 9 |
| 239 | Anorectal Melanoma Metastatic to the Breast. Journal of Clinical Gastroenterology, 1999, 29, 197-199. | 1.1 | 12 |
| 240 | A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-â€œfluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Cancer, 1998, 83, 2475-2480. | 2.0 | 11 |
| 241 | Magnetic resonance imaging of bone marrow versus biopsy in malignant lymphoma. European Journal of Cancer, 1997, 33, S270. | 1.3 | 0 |
| 242 | Generalized telangiectasia as the major manifestation of angiotropic (intravascular) lymphoma. British Journal of Dermatology, 1997, 137, 422-425. | 1.4 | 38 |